TME PHARMA N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.249 EUR | +0.20% |
|
-0.99% | +8.26% |
| Sales 2022 | - | Sales 2023 | 0.02 0.02 1.36 | Capitalization | 1.22M 1.14M 97.62M |
|---|---|---|---|---|---|
| Net income 2022 | -15M -14.03M -1.2B | Net income 2023 | -6M -5.61M -480M | EV / Sales 2022 | - |
| Net cash position 2022 | 548K 513K 43.87M | Net cash position 2023 | 966K 903K 77.33M | EV / Sales 2023 | 14,912,294 x |
| P/E ratio 2022 |
-0.09
x | P/E ratio 2023 |
-0.17
x | Employees | 13 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.38% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.20% | ||
| 1 week | -0.99% | ||
| Current month | -20.70% | ||
| 1 month | -20.70% | ||
| 3 months | +18.01% | ||
| 6 months | -36.40% | ||
| Current year | +8.26% |
1 week
0.23
0.28
1 month
0.230.44
Current year
0.210.44
1 year
0.192.20
3 years
0.1952.00
5 years
0.19123.00
10 years
0.192 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 30/04/10 | |
Heike Balzer
DFI | Director of Finance/CFO | - | 31/12/99 |
Ewelina Staniuk
IRC | Investor Relations Contact | - | 31/12/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 29/06/20 | |
| Chairman | 76 | 31/08/16 | |
Susan Coles
BRD | Director/Board Member | 58 | 23/06/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.249 | +0.20% | 385,003 |
| 25/04/24 | 0.2485 | -4.05% | 126,726 |
| 24/04/24 | 0.259 | +0.97% | 432,690 |
| 23/04/24 | 0.2565 | +0.98% | 424,986 |
| 22/04/24 | 0.254 | +0.99% | 270,207 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotes
TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Calendar
23/10/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.26% | 7.56M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ALTME Stock
